1	Mutational alterations in the QRDR regions associated with fluoroquinolone resistance in
2	Pseudomonas aeruginosa of clinical origin from Savar, Dhaka
3	Md. Shamsul Arefin <sup>1</sup> ¶, Meftahul Jannat Mitu <sup>1</sup> ¶, Shomaia Yasmin Mitu <sup>1</sup> , Azmeri Noorjahan <sup>2</sup> , Mir
4	Mobin <sup>1</sup> , Shamsun Nahar <sup>1</sup> , Hasnain Anjum <sup>1,3*</sup> , M. Hasibur Rahman <sup>1*</sup>
5	<sup>1</sup> Department of Microbiology, Jahangirnagar University, Savar, Dhaka.
6	<sup>2</sup> Department of Biotechnology and Genetic Engineering, Jahangirnagar University, Savar, Dhaka
7	<sup>3</sup> Department of Microbiology, Primeasia University, Banani, Dhaka.
8	
9	* Corresponding Authors
10	Email: anjumabir27@gmail.com (HA); hasiburku@juniv.edu (MHR)
11	
12	¶MSA and MJM contributed equally to this study.
13	
14	
15	
16	
17	
18	
19	

20

21

22

23

24

25

26

27

28

29

30

31

32

33

34

35

36

37

38

39

40

41

Mutational alterations in the QRDR regions associated with fluoroquinolone resistance in Pseudomonas aeruginosa of clinical origin from Savar, Dhaka **Abstract** Bacterial DNA gyrase and topoisomerase IV are the major targets of quinolone antibiotic, and mutational alterations in quinolone resistance determining regions (QRDR) serve as major mechanism of resistance in most bacterial species, including P. aeruginosa. The present investigation was aimed to study the molecular mechanism of fluoroquinolone resistance among clinical P. aeruginosa isolated from Dhaka, including alterations in target sites of the antimicrobial action. Laboratory collection of 53 P. aeruginosa were subjected to conventional cultural and biochemical characterization, followed by molecular identification using 16S rDNA sequencing. Susceptibility to ciprofloxacin and levofloxacin was tested by disc diffusion method followed by MIC assay. Resistant isolates were analyzed for mutation in their QRDR regions of gyrA and parC, and subjected to PCR detection of plasmid mediated quinolone resistance (PMQR) genes qnrA, qnrS and qnrB. Among the isolates, 28% were found to be resistant to both fluoroquinolones tested. All of the fluoroquinolone resistant isolates carried a single mutation in gyr4 (Thr-83-Ile), while 20% carried a single parC mutation (Ser-87-Leu). Higher level of MIC was observed in isolates carrying alterations at both sites. None of the isolates harbored any PMQR genes investigated, suggesting that chromosomal mutations in QRDR regions to be the major contributing factor for quinolone resistance in P. aeruginosa under investigation.

**Keywords:** Pseudomonas aeruginosa, Fluoroquinolone resistance, QRDR, PMQR

## **Introduction:**

42

43

44

45

46

47

48

49

50

51

52

53

54

55

56

57

58

59

60

61

62

63

64

Pseudomonas aeruginosa is a cosmopolitan member of the Pseudomonaceae family commonly associated with opportunistic and nosocomial infections [1]. The recent emergence of multidrug-resistant and extensively-drug resistant strains of P. aeruginosa is alarming, indicating diminished options of therapeutically effective antibiotics [2]. The nosocomial pathogen can naturally resist a wide range of antibiotics through lower outer membrane permeability, multidrug efflux pumps and chromosomally encoded enzymes [2-4]. Antibiotics like carbapenems, fluoroquinolones, piperacillin, ceftazidime and aminoglycosides are commonly used for treatment of infection caused by P. aeruginosa [5]. However, emerging resistance to these antibiotics has been creating outbreaks of multidrug resistant isolates, which is becoming a major infection-related treatment burden [6]. Resistance to drugs like quinolone in P. aeruginosa increases difficulties in treating severe infections like sepsis and catheter-associated urinary tract infection (CA-UTI) [7]. Fluoroquinolone antibiotics, including ciprofloxacin and levofloxacin, can inhibit DNA Gyrase and Topoisomerase of *P. aeruginosa*, leading to bacteriostatic activity [8]. Resistance to these antibiotics is primarily mediated through mutational alterations in the QRDR motif [9]. In P. aeruginosa, fluoroquinolone target includes DNA Gyrase (GyrA and GyrB) and DNA Topoisomerase IV (ParC and ParE) molecular subunits, which are responsible for ATP-dependent cleaving and rebinding doublestranded DNA during replication [10]. Fluoroquinolones can bind to GyrA and/or ParC subunits and inhibit the catalytic effect of the protein, resulting inhibition of bacterial DNA replication [11]. Amino acid substitution in the 67-106 motif of the GyrA subunit of P. aeruginosa has been reported as the major mechanism of resistance against the antibiotic, as it leads to a reduced binding affinity between fluoroquinolones and GyrA [12-13]. Evidence suggests that substitution of amino acid residues Thr83 of the ORDR motif in GyrA is essential for the development of quinolone-resistant P. aeruginosa [13-15]

Additional mutational alteration in the QRDR motif of ParC subunit of DNA topoisomerase IV has also

been associated with increased level of quinolone resistance in *P. aeruginosa* [13].

Alongside mutational alteration in the QRDR motif of GyrA and ParC, other resistance mechanisms also

significantly contribute to reduced quinolone sensitivity in *P. aeruginosa*. This includes overexpression of

efflux molecular pumps like MexAB-OprM and MexCD-OprJ through mutational alterations in their

regulatory genes mexR and nfxB, respectively [16], and acquisition of PMQR genes like qnrA, qnrB, qnrC

and qnrS [17]. Therefore, the aim of the present study was to investigate the DNA sequences of P.

aeruginosa QRDR motifs to understand the association of fluoroquinolone tolerance level and alteration in

GyrA and ParC, as well as the prevalence of PMQR variants in clinical P. aeruginosa isolates from

Bangladesh.

65

66

67

68

69

70

71

72

73

74

75

76

77

78

79

80

81

82

83

84

85

### **Materials and Methods:**

#### **Bacterial Isolates:**

Laboratory collection of 53 clinical P. aeruginosa collected from two renowned hospitals in Savar was

investigated in this study. Sample types included urine, pus, secondary wound infection swab, burn wounds,

catheter swab blood and tracheal aspirate. Reconfirmation of the isolates' identity was conducted using

conventional cultural and biochemical characterization following Bargey's Manual of Systemic

Bacteriology [18-20]. For further verification of their identity, fourteen representative isolates from

different antibiotic resistance pattern were subjected to 16SrDNA sequencing using fd1 and rp2 primers

(Table 1) and identity of the isolates was confirmed by BLAST analysis of the sequences using an online

database (https://blast.ncbi.nlm.nih.gov/Blast.cgi).

## Screening of fluoroquinolone resistance in clinical *P. aeruginosa*:

86

87

88

89

90

91

92

93

94

95

96

97

98

99

100

101

102

103

104

105

106

Fluoroquinolone susceptibility among the clinical P. aeruginosa isolates were determined by disc diffusion assay against Ciprofloxacin and Levofloxacin, followed by minimum inhibitory concentration analysis by agar dilution method. Results were interpreted according to Clinical Laboratory Standard Institute (CLSI) standards [21]. P. aeruginosa ATCC 27853 was used as control for this experiment. **Sequence analysis of the QRDRs in GyrA and ParC:** Fluoroquinolone resistant isolates were subjected to analysis of alterations in their GyrA and ParC subunits of DNA Gyrase and Topoisomerase IV, respectively. The amplification of putative QRDR region in gyrA and parC gene was carried out using primer sequence and conditions obtained from a previous study [22]. Purified PCR-amplified products were sequenced by the dideoxy chain-termination method [46]. Sequence alignment and amino acid alterations were analyzed by Bioedit Sequence Alignment Editor (version 7.0.5.3). The sequences were compared with associated *P. aeuginosa* PAO1 loci from NCBI GenBank as reference. PCR Amplification of Plasmid Mediated Quinolone Resistance (PMQR) genes: The presence of three different variants of qnr genes namely qnrA, qnrB and qnrS were investigated in all isolates exhibiting phenotypic resistance against fluoroquinolone antibiotics. The primers and annealing temperatures are enlisted in Table 1.

#### Table 1. Primers used in this study

107

Gene	Primer Sequence (5' to 3')	Use	Annealing	Amplicon	Reference
			Temperature	Size/	
				Nucleotide	
				Position	
gyrA	GAC GGC CTG AAG CCG GTG CAC	Amplification and sequencing of	65°C	115-135	[22]
	GCC CAC GGC GAT ACC GCT GGA	GyrA subunit of Toposiomerase II		531-511	
parC	CGA GCA GGC CTA TCT GAA CTA T	Amplification and sequencing of	55°C	63-84	
	GAA GGA CTT GGG ATC GTC CGG A	parC subunit of Toposiomerase IV		366-344	
qnrA	AGA GGA TTT CTC ACG CCA GG	Amplification of QnrA	54°C	580bp	[23]
	TGC CAG GCA CAG ATC TTG AC				
qnrB	CCT GAG CGG CAC TGA ATT TAT	Amplification of QnrB	60°C	390bp	[24]
	GTT TGC TGC TCG CCA GTC GA				
qnrS	GCA AGT TCA TTG AAC AGG GT	Amplification of QnrS	54°C	428bp	[23]
	TCT AAA CCG TCG AGT TCG GCG				
fd1	TCT AAA CCG TCG AGT TCG GCG	Amplification and sequencing of 16S	42°C	1500bp	[25]
rp2	ACG GCT ACC TTG TTA CGA CTT	rDNA			

# **Results:**

108

109

110

# Fluoroquinolone resistance in P. aeruginosa:

- All 53 isolates of *P. aeruginosa* were subjected to fluoroquinolone susceptibility test against ciprofloxacin
- and levofloxacin by disk-diffusion method followed by minimum inhibitory concentration (MIC) assay.

Among them, 15 (28%) were found to be resistant to both ciprofloxacin and levofloxacin, and all resistant isolates exhibited a high tolerance level to the fluoroquinolones tested ( $\geq$ 16 to  $\geq$ 128 µg/ml).

# **Sequence analysis of QRDR regions:**

The amino acid alterations in GyrA and ParC QRDR regions of 15 fluoroquinolone resistant *P. aeruginosa* was analyzed by sequencing and comparing with the corresponding sequences of *P. aeruginosa* PAO1. According to the pattern of amino acid alteration, the isolates were categorized into two distinct groups. Group I consisted of isolates with a single mutation at Thr-83-Ile in *gyrA*, while Group II contained one mutation at Thr-83-Ile in *gyrA* and one mutation at Ser-87-Leu in *parC* (Table 2). Among the 15 isolates, all carried a single mutation (Thr-83-Ile) in *gyrA*. Single mutation in *parC* (Ser-87-Leu) was also found in 3 of 15 isolates (19%). No additional mutations were observed in the QRDR regions. Sequence data of *gyrA* and *parC* from a representative isolate carrying mutations at both sites (PWS10) have been submitted to the GenBank databases under accession numbers PP501828 (*gyrA*) and PP526740 (*parC*).

Table 2. Amino acid alterations in gyrA and parC in fluoroquinolone resistant P. aeruginosa isolates

	No. of Isolates	Alterations in QRDR					
Groups		gyrA at position	parC at position				
		83	87				
PAO1		Thr (ACC)	Ser (TCG)				
I	12	Ile (ATC)	-				
II	3	Ile (ATC)	Leu (TTG)				

QRDR mutations in both gyrA and parC subunit reveals high level of tolerance against both ciprofloxacin and levofloxacin (MIC value  $\geq 128~\mu g/ml$ ) (Table 3). Isolates with a single gyrA mutation had fluoroquinolone MIC ranges from 16 to 64  $\mu g/ml$ .

Table 3. Association of mutations in QRDR region and tolerance level against fluoroquinolones

No. of	of Fluoroquinolone No. of isolates with corresponding					g MIC	MIC (μg/ml) value			
Isolates	antibiotics	0.5	1	2	4	8	16	32	64	128
12	Ciprofloxacin						5	5	2	
Single alteration in							1	6	5	
	Levofloxacin									
3	Ciprofloxacin									3
Alterations in gyrA										3
	Levofloxacin									
	Isolates 12	12 Ciprofloxacin  Levofloxacin  3 Ciprofloxacin	Isolates antibiotics — 0.5  12 Ciprofloxacin  Levofloxacin  3 Ciprofloxacin	Isolates antibiotics 0.5 1  12 Ciprofloxacin  Levofloxacin  3 Ciprofloxacin	Isolates antibiotics 0.5 1 2  12 Ciprofloxacin  Levofloxacin  3 Ciprofloxacin	Isolates antibiotics   O.5 1 2 4  Ciprofloxacin  Levofloxacin  Ciprofloxacin	Isolates antibiotics  O.5 1 2 4 8  Ciprofloxacin  Levofloxacin  Ciprofloxacin	Isolates         antibiotics         0.5         1         2         4         8         16           12         Ciprofloxacin         5           Levofloxacin         1           3         Ciprofloxacin	Isolates         antibiotics         0.5         1         2         4         8         16         32           12         Ciprofloxacin         5         5           Levofloxacin         1         6           Action of the complex of th	Isolates         antibiotics         0.5         1         2         4         8         16         32         64           12         Ciprofloxacin         5         5         2           1         6         5           Levofloxacin         3         Ciprofloxacin

## **Occurrence of PMQR genes:**

PCR detection of three PMQR variants (*qnrA*, *qnrB* and *qnrS*) revealed that none of the 15 fluoroquinolone resistant isolates carried the PMQR genes (Fig 1).

**Fig 1. PCR based detection of PMQR variants**. Variants *qnr* gene sequences were PCR amplified using specific primers (Table 1). PCR products were electrophoresed through 1% agarose gels, stained with ethidium bromide, and visualized with UV light. The 100 bp DNA ladder indicates the size of PCR products. Lane 2, 6 and 10 represent variant-specific positive controls, and lane 3, 7 and 11 represent negative controls. No isolates were positive in *qnr*A, *qnr*B and *qnr*S specific PCR.

# **Discussion:**

140

141

142

143

144

145

146

147

148

149

150

151

152

153

154

155

156

157

158

159

160

161

162

163

Pseudomonas aeruginosa can employ multiple mechanisms to resist therapeutically important antibiotics like the fluoroquinolones. Beside decreased level of antibiotic accumulation using lower outer membrane permeability and active molecular efflux pumps, alteration of QRDR motifs within topoisomerase II (GyrA and GyrB subunits) and topoisomerase IV (ParC and ParE subunits) has been considered to be the principal mechanism of fluoroquinolone resistance [26-29]. Several important pathogens, including E. coli, Staphylococcus aureus, Streptococcus pneumoniae and Neisseria gonorrhoeae has been found to have gyrA as their primary target of mutation alone or in combination with parC gene [14, 30-32]. Additional mutation of mexR, nfxC or nfxB genes are also found to cause limited sensitivity to quinolones [13, 33-34]. In Pseudomonas aeruginosa, alteration at position 83 in gyrA is most commonly associated with high level of resistance [12, 35]. Mutation from Threonine to a hydrophobic amino acid at this position tends to generally confer more resistance than other similar alterations at position 87, as observed in several reports [12-14]. The present study observed that all fluoroguinolone resistant isolates carried a single mutation at position 83, where threonine (Thr) was replaced with Isoleucine (Ile) (Table 2). The result is in accordance with previous studies, as it is reported as the most common site of mutation at the QRDR region [13-14, 37-38]. Additional novel mutations in gyrA have also been reported, including Asp-87-Asn, Asp-87-Gly and Gln-106-Leu, which often occurs along with alterations at position 83 and associated with high MIC level [15, 38-39]. However, none of the isolates in this study had such alterations at position 87 and 106. Although Thr-83-Ile mutation can result resistance to second-generation quinolones like ciprofloxacin and levofloxacin as observed in this study (Table 3), its effect has been seen to be limited on more recent generation of quinolones like sitafloxacin and clinafloxacin [34]. Substitution of Leu for Ser-87 in parC subunit was observed in three isolates. This substitution is closely associated with fluoroquinolone resistance, and has been reported as a second step mutation in isolates already having a single alteration of gyrA in P. aeruginosa [13, 15]. This supports the present data, as the

isolates with alteration Ser-87-Leu in parC also carried alteration Thr-83-Ile in gyrA. These isolates had a elevated level of both ciprofloxacin and levofloxacin MIC ( $\geq$ 128 µg/ml). Additional mechanism of resistance like overexpression of efflux pump MexAB-OprM by mutational alteration of mexR could also contribute to fluoroquinolone resistance in P. aeruginosa [34]. However, no phenotypic evidence of efflux pump overexpression was observed in efflux inhibitor induced MIC depression assay in this study (data not shown), so analysis of mutation in mexR has not been conducted.

Although variants of PMQR genes like qnrA, qnrB, qnrC, qnrD and qnrS are not frequently found in P. aeruginosa [40], several recent studies have reported the increasing number of occurrences of PMQR genes in clinical P. aeruginosa [41-42]. But none of the quinolone resistant isolates from this study were seen to be harboring any of the three variants of qnr genes tested. Quinolone resistance through acquisition of PMQR genes is a mechanism commonly observed among the members of the Enterobacteriaceae family [43], and was first discovered by Martinez et al. that it could be transmitted to P. aeruginosa in vitro as well [44]. This is a major concern as acquisition of such resistance elements can further diminish the antimicrobial activity of fluoroquinolones [45].

# **Conclusion:**

Culmination of data from this study suggests mutational alteration at QRDR regions, especially GyrA is the most significant mechanism of resistance to fluoroquinolones. Although other mechanisms like acquisition of PMQR and overexpression of efflux pumps contribute to resistance, the results indicate that mutational alteration alone can lead to the development of resistance against second generation fluoroquinolones like ciprofloxacin and levofloxacin. Broad spectrum antibiotics like fluoroquinolones are one of the safest therapeutic options to treat infections caused by *P. aeruginosa*. However, the everincreasing resistance to the antibiotics is a major concern. Due to the bacteria's incredible capacity in acquiring and resisting various antibiotics, it is essential to raise awareness to implement antibiotic stewardship.

188

189

190

191

192

193

194

195

196

197

198

199

200

201

202

203

204

205

206

207

**Data Availability** Sequence data of gvrA and parC from a representative isolate is available at the GenBank databases under Accession numbers PP501828 (gyrA) and PP526740 (parC). **Ethics statement** This study was approved by the Ethics and Research Review Committee of the Jahangirnagar University Faculty of Biological Sciences [Ref No: BBEC, JU/M 2020 (1)4]. Written informed consent was obtained from patients for sample collection, and their personal identities along with other information were anonymized. **Acknowledgments:** The authors would like to thank the laboratory personnel of Enam Medical College Hospital and Gonoshasthaya Medical College Hospital, Dhaka, Bangladesh, for their support in the collection of the clinical samples. **Conflicts of Interest:** The authors declare that they have no conflict of interest. **Reference:** Tümmler B. Emerging therapies against infections with Pseudomonas aeruginosa. F1000Research. 2019;8.. 1. 2. Anjum H, Arefin MS, Jahan N, Oishee MJ, Nahar S, Islam S, et al. Roles of intrinsic and acquired resistance determinants in multidrug-resistant clinical Pseudomonas aeruginosa in Bangladesh. Bangladesh Journal of Medical Science. 2023 Jul 1;22(3). 3. Hancock RE. Resistance mechanisms in Pseudomonas aeruginosa and other nonfermentative gram-negative bacteria. Clinical Infectious Diseases. 1998 Aug 1;27(Supplement 1):S93-9.

- 208 4. Livermore DM. Multiple mechanisms of antimicrobial resistance in Pseudomonas aeruginosa: our worst nightmare?.
- 209 Clinical infectious diseases. 2002 Mar 1;34(5):634-40.
- 210 5. Pachori, P., Gothalwal, R., & Gandhi, P. (2019). Emergence of antibiotic resistance Pseudomonas aeruginosa in intensive
- 211 care unit; a critical review. Genes & diseases, 6(2), 109-119.
- 212 6. Raman, G., Avendano, E. E., Chan, J., Merchant, S., & Puzniak, L. (2018). Risk factors for hospitalized patients with
- 213 resistant or multidrug-resistant Pseudomonas aeruginosa infections: a systematic review and meta-analysis. Antimicrobial
- 214 Resistance & Infection Control, 7, 1-14.
- 215 7. Hsu DI, Okamoto MP, Murthy R, Wong-Beringer A. Fluoroquinolone-resistant Pseudomonas aeruginosa: risk factors
- for acquisition and impact on outcomes. Journal of Antimicrobial Chemotherapy. 2005 Apr 1;55(4):535-41.
- 217 8. Correia S, Poeta P, Hébraud M, Capelo JL, Igrejas G. Mechanisms of quinolone action and resistance: where do we
- stand?. Journal of medical microbiology. 2017 May;66(5):551-9.
- 219 9. Le Thomas I, Couetdic G, Clermont O, Brahimi N, Plesiat P, Bingen E. In vivo selection of a target/efflux double mutant
- of Pseudomonas aeruginosa by ciprofloxacin therapy. Journal of Antimicrobial Chemotherapy. 2001 Oct 1;48(4):553-5.
- 221 10. Bush NG, Evans-Roberts K, Maxwell A. DNA topoisomerases. EcoSal Plus. 2015 Dec 31;6(2):10-128.
- 222 11. Rehman A, Patrick WM, Lamont IL. Mechanisms of ciprofloxacin resistance in Pseudomonas aeruginosa: new
- approaches to an old problem. Journal of Medical Microbiology. 2019 Jan;68(1):1-0.
- 224 12. Madurga S, Sánchez-Céspedes J, Belda I, Vila J, Giralt E. Mechanism of binding of fluoroquinolones to the quinolone
- resistance-determining region of DNA gyrase: Towards an understanding of the molecular basis of quinolone resistance.
- 226 Chembiochem. 2008 Sep 1;9(13):2081-6.
- 227 13. Lee JK, Lee YS, Park YK, Kim BS. Alterations in the GyrA and GyrB subunits of topoisomerase II and the ParC and
- 228 ParE subunits of topoisomerase IV in ciprofloxacin-resistant clinical isolates of Pseudomonas aeruginosa. International journal of
- antimicrobial agents. 2005 Apr 1;25(4):290-5.
- 230 14. Ostrer L, Khodursky RF, Johnson JR, Hiasa H, Khodursky A. Analysis of mutational patterns in quinolone resistance-
- determining regions of GyrA and ParC of clinical isolates. International journal of antimicrobial agents. 2019 Mar 1;53(3):318-24.
- 232 15. Akasaka T, Tanaka M, Yamaguchi A, Sato K. Type II topoisomerase mutations in fluoroquinolone-resistant clinical
- strains of Pseudomonas aeruginosa isolated in 1998 and 1999: role of target enzyme in mechanism of fluoroquinolone resistance.
- Antimicrobial agents and chemotherapy. 2001 Aug 1;45(8):2263-8.

- 235 16. Jalal S, Ciofu O, Høiby N, Gotoh N, Wretlind B. Molecular mechanisms of fluoroquinolone resistance in Pseudomonas
- aeruginosa isolates from cystic fibrosis patients. Antimicrobial agents and chemotherapy. 2000 Mar 1;44(3):710-2.
- 237 17. Cayci YT, Coban AY, Gunaydin M. Investigation of plasmid-mediated quinolone resistance in Pseudomonas aeruginosa
- clinical isolates. Indian journal of medical microbiology. 2014 Jul 1;32(3):285-9.
- 239 18. Brenner DJ, Boone DR, Garrity GM, Goodfellow M, Krieg NR, Rainey FA, et al. The Proteobacteria: Part C: The Alpha-,
- Beta-, Delta-, and Epsilonproteobacteria. Athens, GA, USA: Bergey's Manual Trust; 2005.
- 241 19. Gilardi GL. Characterization of Pseudomonas species isolated from clinical specimens. Applied Microbiology. 1971
- 242 Mar;21(3):414-9.
- 243 20. Cappuccino JG, Sherman N. Microbiology: a laboratory manual. Pearson Higher Ed; 2013 Feb 20.
- 24. CLSI. Performance Standards for Antimicrobial Susceptibility Testing. 31st ed.
- 245 22. Lee JK, Lee YS, Park YK, Kim BS. Alterations in the GyrA and GyrB subunits of topoisomerase II and the ParC and
- ParE subunits of topoisomerase IV in ciprofloxacin-resistant clinical isolates of Pseudomonas aeruginosa. International journal of
- antimicrobial agents. 2005 Apr 1;25(4):290-5.
- 248 23. Cattoir V, Poirel L, Rotimi V, Soussy CJ, Nordmann P. Multiplex PCR for detection of plasmid-mediated quinolone
- resistance qnr genes in ESBL-producing enterobacterial isolates. Journal of antimicrobial chemotherapy. 2007 Aug 1;60(2):394-7.
- 250 24. Wu JJ, Ko WC, Tsai SH, Yan JJ. Prevalence of plasmid-mediated quinolone resistance determinants QnrA, QnrB, and
- 251 QnrS among clinical isolates of Enterobacter cloacae in a Taiwanese hospital. Antimicrobial agents and chemotherapy. 2007
- **252** Apr;51(4):1223-7.
- 253 25. Weisburg WG, Barns SM, Pelletier DA, Lane DJ. 16S ribosomal DNA amplification for phylogenetic study. Journal of
- 254 bacteriology. 1991 Jan;173(2):697-703.
- 255 26. Zhao L, Wang S, Li X, He X, Jian L. Development of in vitro resistance to fluoroquinolones in Pseudomonas aeruginosa.
- Antimicrobial resistance & infection control. 2020 Dec;9:1-8.
- 257 27. Drlica K, Zhao X. DNA gyrase, topoisomerase IV, and the 4-quinolones. Microbiology and molecular biology reviews.
- 258 1997 Sep;61(3):377-92.
- 259 28. Ruiz J. Mechanisms of resistance to quinolones: target alterations, decreased accumulation and DNA gyrase protection.
- Journal of Antimicrobial Chemotherapy. 2003 May 1;51(5):1109-17.

- 26. Komp Lindgren P, Karlsson AS, Hughes D. Mutation rate and evolution of fluoroquinolone resistance in Escherichia
- coli isolates from patients with urinary tract infections. Antimicrobial agents and chemotherapy. 2003 Oct;47(10):3222-32.
- 263 30. Al-Kobaisi MF. Jawetz, Melnick & Adelberg's Medical Microbiology 24th Edition. Sultan Qaboos University Medical
- **264** Journal. 2007 Dec 1;7(3):273-5.
- 265 31. Bhatnagar K, Wong A. The mutational landscape of quinolone resistance in Escherichia coli. PLoS One. 2019 Nov
- **266** 5;14(11):e0224650.
- de Korne-Elenbaas J, Pol A, Vet J, Dierdorp M, van Dam AP, Bruisten SM. Simultaneous detection of Neisseria
- gonorrhoeae and fluoroquinolone resistance mutations to enable rapid prescription of oral antibiotics. Sexually transmitted diseases.
- 269 2020 Apr 1;47(4):238-42.
- 270 33. Ma Z, Xu C, Zhang X, Pan X, Bai F, Cheng Z, Wu W, Jin Y. A MexR mutation which confers aztreonam resistance to
- Pseudomonas aeruginosa. Frontiers in Microbiology. 2021 Jun 24;12:659808.
- Higgins PG, Fluit AC, Milatovic D, Verhoef J, Schmitz FJ. Mutations in GyrA, ParC, MexR and NfxB in clinical isolates
- of Pseudomonas aeruginosa. International journal of antimicrobial agents. 2003 May 1;21(5):409-13.
- 274 35. Sada M, Kimura H, Nagasawa N, Akagawa M, Okayama K, Shirai T, et al. Molecular evolution of the Pseudomonas
- aeruginosa DNA gyrase gyrA gene. Microorganisms. 2022 Aug 17;10(8):1660.
- 36. JALAL S, WRETLIND B. Mechanisms of quinolone resistance in clinical strains of Pseudomonas aeruginosa. Microbial
- **277** Drug Resistance. 1998;4(4):257-61.
- 278 37. Park Y, Oh J, Park S, Sum S, Song W, Chae J, Park H. Antimicrobial resistance and novel mutations detected in the gyrA
- and parC genes of Pseudomonas aeruginosa strains isolated from companion dogs. BMC veterinary research. 2020 Dec;16:1-8.
- 280 38. Oh H, Stenhoff J, Jalal S, Wretlind B. Role of efflux pumps and mutations in genes for topoisomerases II and IV in
- fluoroquinolone-resistant Pseudomonas aeruginosa strains. Microbial Drug Resistance. 2003 Dec 1;9(4):323-8.
- Nakano M, Deguchi T, Kawamura T, Yasuda M, Kimura M, Okano Y, et al. Mutations in the gyrA and parC genes in
- 283 fluoroquinolone-resistant clinical isolates of Pseudomonas aeruginosa. Antimicrobial agents and chemotherapy. 1997
- 284 Oct;41(10):2289-91.
- 285 40. Ude J, Tripathi V, Buyck JM, Söderholm S, Cunrath O, Fanous J, et al. Outer membrane permeability: Antimicrobials
- and diverse nutrients bypass porins in Pseudomonas aeruginosa. Proceedings of the National Academy of Sciences. 2021 Aug
- **287** 3;118(31):e2107644118.

- 288 41. Saki M, Farajzadeh Sheikh A, Seyed-Mohammadi S, Asareh Zadegan Dezfuli A, Shahin M, Tabasi M, et al. Occurrence
- 289 of plasmid-mediated quinolone resistance genes in Pseudomonas aeruginosa strains isolated from clinical specimens in southwest
- Iran: a multicentral study. Scientific Reports. 2022 Feb 10;12(1):2296.
- 291 42. Nabilou M, Babaeekhou L, Ghane M. Fluoroquinolone resistance contributing mechanisms and genotypes of
- 292 ciprofloxacin-unsusceptible Pseudomonas aeruginosa strains in Iran: emergence of isolates carrying qnr/aac (6)-lb genes.
- 293 International Microbiology. 2021:1-1.
- 43. Azargun R, Gholizadeh P, Sadeghi V, Hosainzadegan H, Tarhriz V, Memar MY, et al. Molecular mechanisms associated
- with quinolone resistance in Enterobacteriaceae: review and update. Transactions of the Royal Society of Tropical Medicine and
- 296 Hygiene. 2020 Oct;114(10):770-81.
- 44. Martínez-Martínez L, Pascual A, Jacoby GA. Quinolone resistance from a transferable plasmid. The Lancet. 1998 Mar
- **298** 14;351(9105):797-9.
- 299 45. Rodríguez-Martínez JM, Machuca J, Cano ME, Calvo J, Martínez-Martínez L, Pascual A. Plasmid-mediated quinolone
- resistance: two decades on. Drug Resistance Updates. 2016 Nov 1;29:13-29.
- 301 46. Walker SE, Lorsch J. Sanger dideoxy sequencing of DNA. InMethods in enzymology 2013 Jan 1 (Vol. 529, pp. 171-
- 302 184). Academic Press.

